Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | CPA3 | P15088 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571474 | 0.87 | MME (0.47) | CYP1A2MMECPA1CPA3FOLH1 | |
| SCHEMBL7378715 | 0.85 | CYP1A2 (0.65) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL27719461 | 0.85 | CYP1A2 (0.47) | CYP1A2MMECPA1CPA3FOLH1 | |
| SCHEMBL2028390 | 0.84 | SLC7A5 (0.53) | CYP1A2MMECPA1CPA3FOLH1 | |
| SCHEMBL2396464 | 0.84 | CYP1A2 (0.70) | CYP1A2MMECPA1CPA3FOLH1 | |
| SCHEMBL7436701 | 0.83 | CYP1A2 (0.57) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7436695 | 0.83 | CYP1A2 (0.57) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1915415 | 0.82 | LDHA (0.63) | CYP1A2PPARGPPARAKMT2A | |
| SCHEMBL6790718 | 0.81 | GRIK1 (0.45) | CYP1A2MMEPPARGPPARAMEN1 | |
| SCHEMBL11529738 | 0.80 | CYP1A2 (0.59) | CYP1A2CPA1CPA3PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | CYP1A2 180/4885MME 1287/4885CPA1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.